Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore; Cancer research centre of Lyon (CRCL), INSERM U1052, Lyon, France.
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore.
Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):755-759. doi: 10.1016/j.clinre.2015.12.011. Epub 2016 Feb 2.
With an increasing incidence of non-alcoholic fatty livers, the existence of concomitant hepatitis B and fatty liver is becoming more common in clinical practice. In clinical practice, the concomitant existence of hepatitis B and fatty livers raises practical issues in clinical management. It becomes more difficult for the clinician to decide on the mode of treatment in the case of elevated Alanine aminotransferase (ALT) and in deciding potential causes, whether they are related to chronic hepatitis B or to non-alcoholic steatohepatitis (NASH). With evolving changes in the practice and knowledge of non-alcoholic fatty liver disease and chronic hepatitis B, clinical judgment on the predominant disease becomes essential for their coexistence. This short review is aimed at reviewing the evidence available on the frequency of the two diseases existing concomitantly, possible ways of differentiating the two, the prognosis, outcomes of treatment and a possible common pathway.
随着非酒精性脂肪肝的发病率不断上升，乙型肝炎和脂肪肝同时存在的情况在临床实践中越来越常见。在临床实践中，乙型肝炎和脂肪肝同时存在给临床管理带来了实际问题。在丙氨酸氨基转移酶（ALT）升高的情况下，以及在确定潜在原因时，无论是与慢性乙型肝炎还是非酒精性脂肪性肝炎（NASH）有关，临床医生更难决定治疗方式。随着非酒精性脂肪肝和慢性乙型肝炎实践和知识的不断发展，对两者共存时主要疾病的临床判断变得至关重要。这篇简短的综述旨在回顾关于这两种疾病同时存在的频率、区分两者的可能方法、预后、治疗结果和可能的共同途径的现有证据。
